These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 15272475

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Neuroleptic treatments and overflow movements in schizophrenia: are they independent?
    D'Agati E, Casarelli L, Pitzianti M, Pasini A.
    Psychiatry Res; 2012 Dec 30; 200(2-3):970-6. PubMed ID: 22901438
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Understanding aberrant white matter development in schizophrenia: an avenue for therapy?
    Walterfang M, Velakoulis D, Whitford TJ, Pantelis C.
    Expert Rev Neurother; 2011 Jul 30; 11(7):971-87. PubMed ID: 21721915
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Preliminary study of schizophrenics with brain atrophy treated with antipsychotic drugs].
    Wang XY.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1988 Oct 30; 21(5):294-6, 319. PubMed ID: 2906857
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Neurobiology and treatment of mentalisation in schizophrenia].
    Herold R, Tényi T.
    Neuropsychopharmacol Hung; 2005 Dec 30; 7(4):187-93. PubMed ID: 16496483
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Disturbance of oligodendrocyte differentiation in schizophrenia in relation to main hypothesis of the disease].
    Kolomeets NS.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017 Dec 30; 117(8):108-117. PubMed ID: 28884727
    [Abstract] [Full Text] [Related]

  • 18. Microglial activation in schizophrenia and minocycline treatment.
    Hashimoto K.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct 01; 32(7):1758-9; author reply 1760. PubMed ID: 18652869
    [No Abstract] [Full Text] [Related]

  • 19. Schizophrenia: new pathological insights and therapies.
    Jarskog LF, Miyamoto S, Lieberman JA.
    Annu Rev Med; 2007 Oct 01; 58():49-61. PubMed ID: 16903799
    [Abstract] [Full Text] [Related]

  • 20. [First and second generation antipsychotics and morphological and neurochemical brain changes in schizophrenia. Review of magnetic resonance imaging and proton spectroscopy findings].
    Szulc A.
    Psychiatr Pol; 2007 Oct 01; 41(3):329-38. PubMed ID: 17900049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.